

a membrane and a major histocompatibility complex (MHC) protein or a functional derivative or fragment thereof.


**REMARKS**

The amendments to the specification are to correct typographical errors. The remaining amendments are to put the claims from the PCT application into traditional US format and to correct typographical errors. Support for the amendments is in the claims as filed. Support for new Claims 11, 12 and 13 is found for example at page 9, lines 11-20; and page 2, lines 14 to page 4, line 3.

No new matter is added by the above amendments and the Examiner is requested to enter the amendments.

Respectfully submitted,

Date: February 2, 1998



Viola T. Kung, Ph.D.  
Reg. No. 41,131

Rae-Venter Law Group, P.C.  
P.O. Box 60039  
Palo Alto, CA 94306  
Telephone: (650) 328-4400  
Facsimile: (650) 328-4477

BRV/amp RILE.001.00US PRELIM AMEND 012998